Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2020 2019 2020 2019 Net Earnings, after tax- as reported $3,626 $5,607 $9,422 $9,356 Pre-tax Adjustments Intangible Asset Amortization expense 1,127 1,118 2,245 2,248 Litigation expense, net 613 409 733 832 IPR&D 6 - 6 890 Restructuring related 115 142 233 232 Acquisition and Integration related ¹ 29 55 (933) 122 Unrealized (gains)/losses on securities (533) (148) (206) (306) Medical Device Regulation 2 37 - 51 - Other 3 (3) 3 - Tax Adjustments Tax impact on special item adjustments 3 (253) (230) (520) (763) Tax legislation and related impacts (324) - (434) - Adjusted Net Earnings, after tax $4,446 $6,950 $10,600 $12,611 Average shares outstanding (Diluted) 2,665.5 2,691.7 2,671.0 2,697.0 Adjusted net earnings per share (Diluted) $1.67 $2.58 $3.97 $4.68 Operational adjusted net earnings per share (Diluted) $1.69 $4.01 Notes: 1 2 3 Second Quarter Six Months Ended Acquisition and integration related costs for the six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 1 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure WW As Reported (7.0)% 2.1% (33.9)% (10.8)% U.S. 1.3% 5.8% (39.6)% (8.3)% International (13.4)% (2.4)% (28.8)% (13.4)% WW Currency (3.4) (1.8) (1.2) (1.8) U.S. - - - - International (6.0) (3.8) (2.4) (3.8) WW Operational (3.6)% 3.9% (32.7)% (9.0)% U.S. 1.3% 5.8% (39.6)% (8.3)% International (7.4)% 1.4% (26.4)% (9.6)% General Surgery Advanced Sterilization Products 0.1 0.1 U.S. 0.0 0.0 International 0.3 0.2 Baby Care Baby Center 0.3 0.0 U.S. 0.7 0.1 International 0.0 0.0 All Other Acquisitions and Divestitures 0.0 0.0 0.1 0.1 U.S. 0.0 0.0 0.1 0.0 International (0.1) 0.1 0.0 0.0 WW Adjusted Operational (3.4)% 3.9% (32.5)% (8.8)% U.S. 2.0% 5.8% (39.5)% (8.1)% International (7.5)% 1.5% (26.1)% (9.4)% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth SECOND QUARTER 2020 ACTUAL vs. 2019 ACTUAL Segments Consumer Health Pharmaceutical Medical Devices Total -- 2 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure WW As Reported 0.9% 5.4% (21.1)% (3.8)% U.S. 10.8% 7.2% (23.1)% (1.4)% International (6.8)% 3.2% (19.2)% (6.3)% WW Currency (2.7) (1.6) (1.3) (1.6) U.S. - - - - International (4.9) (3.5) (2.4) (3.4) WW Operational 3.6% 7.0% (19.8)% (2.2)% U.S. 10.8% 7.2% (23.1)% (1.4)% International (1.9)% 6.7% (16.8)% (2.9)% Skin Health / Beauty Dr. Ci Labo - Japan (0.2) 0.0 U.S. 0.0 0.0 International (0.4) (0.1) General Surgery Advanced Sterilization Products 1.0 0.4 U.S. 1.1 0.4 International 0.9 0.4 Baby Care Baby Center 0.3 0.0 U.S. 0.7 0.1 International 0.0 0.0 All Other Acquisitions and Divestitures (0.1) 0.1 0.0 0.0 U.S. 0.0 0.1 0.0 0.1 International (0.2) 0.0 0.0 0.0 WW Adjusted Operational 3.6% 7.0% (18.8)% (1.7)% U.S. 11.5% 7.2% (22.0)% (0.8)% International (2.5)% 6.7% (15.9)% (2.6)% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth SIX MONTHS 2020 ACTUAL vs. 2019 ACTUAL Segments Consumer Health Pharmaceutical Medical Devices Total -- 3 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Reported Income Before Tax by Segment $ 32 406 4,514 3,677 (354) 3,189 (252) (231) 3,940 7,041 % to Sales 1.0% 11.5% 42.0% 34.9% -8.3% 49.1% -1.4% -1.1% 21.5% 34.2% Intangible asset amortization expense 102 124 779 754 246 240 - - 1,127 1,118 In-process research and development - - - - 6 - - - 6 - Litigation expense, net 638 172 (58) 26 33 211 - - 613 409 Unrealized loss/(gain) on securities - 1 (522) (151) (11) 2 - - (533) (148) Restructuring related 20 37 21 19 74 86 - - 115 142 Acquisition and integration related - - 10 51 19 4 - - 29 55 Medical Device Regulation - - - - 37 - - - 37 - Other - - - - 3 (3) - - 3 (3) Adjusted Income Before Tax by Segment $ 792 740 4,744 4,376 53 3,729 (252) (231) 5,337 8,614 % to Sales 24.0% 20.9% 44.1% 41.6% 1.2% 57.5% -1.4% -1.1% 29.1% 41.9% *Estimated as of 07/16/2020. Q2 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 4 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 Reported Income Before Tax by Segment $ 802 1,147 8,348 6,008 1,671 4,686 (372) (378) 10,449 11,463 % to Sales 11.6% 16.7% 38.1% 28.9% 16.4% 36.2% -1.0% -0.9% 26.8% 28.2% Intangible asset amortization expense 202 203 1,550 1,561 493 484 - - 2,245 2,248 In-process research and development - - - 890 6 - - - 6 890 Litigation expense, net 638 180 35 351 60 301 - - 733 832 Unrealized loss/(gain) on securities 1 (3) (208) (294) 1 (9) - - (206) (306) Restructuring related 38 44 41 44 154 144 - - 233 232 Acquisition and integration related - - 19 90 (952) 32 - - (933) 122 Medical Device Regulation - - - - 51 - - - 51 - Other - - - - 3 - - - 3 - Adjusted Income Before Tax by Segment $ 1,681 1,571 9,785 8,650 1,487 5,638 (372) (378) 12,581 15,481 % to Sales 24.3% 22.9% 44.7% 41.6% 14.6% 43.5% -1.0% -0.9% 32.2% 38.1% *Estimated as of 07/16/2020. Q2 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 5 of 6 -- Second Quarter Second Quarter June 28, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other June 28, 2020 Non-GAAP Cost of products sold 6,579 $ (1,127) (22) (8) 5,422 Selling, marketing and admin expenses 4,993 (6) 4,987 Research and development expense 2,707 (5) (23) 2,679 Other (Income) / Expense 24 - (613) (32) (24) 533 (3) (115) In-process research and development 6 (6) - Restructuring 61 (61) - Provision for taxes on income 314 217 123 1 22 4 (122) 7 324 1 891 Net Earnings 3,626 910 490 5 93 25 (411) 30 (324) 2 4,446 Second Quarter Second Quarter June 30, 2019 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other June 30, 2019 Non-GAAP Cost of products sold 6,940 $ (1,080) (38) - 5,822 Other (Income) / Expense (1,683) (38) (409) (47) (55) 148 3 (2,081) Restructuring 57 (57) - Provision for taxes on income 1,434 139 67 26 5 (31) 24 1,664 Net Earnings 5,607 979 342 116 50 (117) (27) 6,950 Six Months Six Months June 28, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related (1) Medical Device Regulation Other June 28, 2020 Non-GAAP Cost of products sold 13,641 $ (2,245) (37) (22) 11,337 Selling, marketing and admin expenses 10,196 (6) 10,190 Research and development expense 5,287 (5) (23) 5,259 Other (Income) / Expense (655) - (733) (77) 938 206 (3) (324) In-process research and development 6 (6) - Restructuring 119 (119) - Provision for taxes on income 1,027 363 143 1 43 7 (47) 9 434 1 1,981 Net Earnings 9,422 1,882 590 5 190 (940) (159) 42 (434) 2 10,600 Six Months Six Months June 30, 2019 GAAP Intangible asset amortization Litigation expense, net Restructuring related Acquisition related Medical Device Regulation Other June 30, 2019 Non-GAAP Cost of products sold 13,555 $ (2,210) (61) 11,284 Other (Income) / Expense (1,705) (38) (832) (78) (122) 306 (2,469) In-process research and development 890 (890) - Restructuring 93 (93) - Provision for taxes on income 2,107 423 148 187 41 12 (64) 16 2,870 Net Earnings 9,356 1,825 684 703 191 110 (242) (16) 12,611 (1) Primarily includes a $983 million Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts Year to Date In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development Unrealized (loss)/gain on securities Tax legislation and related impacts -- 6 of 6 --